Concurrent chemotherapy
Phase 3
Concurrent chemotherapy is one of 6 therapeutic programs targeting NSCLC (Non-small Cell Lung Cancer). It is currently in Phase 3.
2
Indications
4
Total Trials
2
Active Trials
5
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
7 competitors in NSCLC (non-Small Cell Lung Cancer)
#DrugCompanyPhaseTrials
1Gavreto
RRigel Pharmaceuticals
Approved
Rasonque
Revolution MedicinesPhase 3
Beyfortus
BeiGenePhase 2
PD-1/PD-L1 Inhibitor
SSecond Affiliated Hospital of Soochow University
Phase 3
Surufatinib
HHutchison Medipharma Limited
Phase 2
Concurrent chemotherapy
SSun Yat-sen University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Unresectable Pancreatic Cancer1 trial
Cervival Cancer1 trial
Non-Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Concurrent chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company
- SSun Yat-sen University